Novavax applies to WHO for emergency listing of COVID-19 vaccine
|CTVnews 23 Sep 2021 at 11:29|
Novavax and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax s COVID-19 vaccine, the company said on Thursday.
The WHO s emergency use listing is a signal to national regulatory authorities on a product s safety and efficacy.
It is also a prerequisite for export to several countries participating in the COVAX vaccine-sharing facility.
Novavax has said it would focus on low- and middle-income countries for initial supplies of the vaccine, as the United States and other Western nations have already vaccinated a large part of their populations with other vaccines.
Novavax had previously said it would apply for the listing in August, marking a slight delay in the filing.
Novavax and Serum Institute, the world s largest vaccine producer, have committed to together provide more than 1.1 billion doses to the COVAX facility, which aims to provide equitable access to COVID-19 vaccines to low- and middle-income countries.
The Novavax shot is a protein-based vaccine, and was shown to be more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.